Just - Evotec Biologics expands tech partnership for biosimilars with Sandoz

EQS-News: Evotec SE / Key word(s): Miscellaneous
Just - Evotec Biologics expands tech partnership for biosimilars with Sandoz

08.07.2024 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

   * Just - Evotec Biologics expands partnership with Sandoz for
   development and commercial manufacturing of biosimilars

   * Additional biosimilars potentially to be added to Sandoz
   development pipeline

* Further guarantees for Sandoz long-term commercial supply security

Hamburg, Germany, and Seattle, WA, USA, 8 July 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX , ISIN: DE0005664809;
NASDAQ: EVO) today announced that its biologics segment, Just - Evotec
Biologics, Inc., has expanded its strategic partnership with Sandoz. Just -
Evotec Biologics will receive appropriate remuneration following early
scientific validation, with further funding tied to achieving development
milestones from 2025.

This expanded partnership solidifies Just - Evotec Biologics' commitment to
providing long-term commercial supply of biosimilars to Sandoz from its
newly built J.POD® biologics manufacturing facility at Evotec's Campus Curie
in Toulouse, France. Sandoz secures further guarantees relating to long-term
supply for patients with a reservation of significant commercial
manufacturing capacity.

Since May 2023, Just - Evotec Biologics and Sandoz have been engaged in a
multi-year technology partnership aimed at the rapid development and
manufacturing of biosimilars. Leveraging its data-driven, fully integrated
design capability and continuous manufacturing technology platform
(J.DESIGN), Just - Evotec Biologics aims to deliver the highest product
quality and cost efficiency to its partners. This collaboration aligns with
Evotec's mission to improve access to medicines for patients across the
globe.

Dr Matthias Evers, Chief Business Officer of Evotec, commented: "We are
thrilled to expand our partnership with Sandoz, building on the successes
we've achieved since the initial launch. Introducing additional molecules
has the potential to enhance access for millions of patients, while
commercial manufacturing from Toulouse will ensure the long-term supply of
Sandoz' biosimilar portfolio. This commercial supply aspect also validates
our strategy to establish our second J.POD® in Toulouse."

About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and
biosimilar medicines, with a growth strategy driven by its Purpose:
pioneering access for patients. 20,000 people of more than 100 nationalities
work together to ensure 800 million patient treatments are provided annually
by Sandoz, generating substantial global healthcare savings and an even
larger total social impact. Its leading portfolio of 1,500 products
addresses diseases from the common cold to cancer. Headquartered in Basel,
Switzerland, Sandoz traces its heritage back to the year 1886. Its history
of breakthroughs includes Calcium Sandoz in 1929, the world's first oral
penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz
achieved sales of USD 9.6 billion.

About Just - Evotec Biologics
Just - Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry
biologics platform company that leverages AI/ML technologies and
world-leading molecular design, cell line development, process
intensification and continuous manufacturing strategies to advance
biotherapeutics from discovery through clinical stages to commercial launch.
The Just - Evotec Biologics team combines deep industry experience in the
fields of data, protein, process, and manufacturing sciences including
automation with highly integrated and flexible capabilities to break through
the scientific and economic barriers associated with the development of
protein therapeutics. Our focus is to accelerate and expand access to
biotherapeutics through scientific and technological innovation for our
proprietary projects and on behalf of our partners. Learn more at
www.just-evotecbiologics.com.

About Evotec SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec provides high value pipeline
co-creating partnerships and solutions to all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare
stakeholders. Evotec has strategic activities in a broad range of currently
underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for innovative
therapeutics and has to-date established a portfolio of more than 200
proprietary and co-owned R&D projects from early discovery to clinical
development. Evotec operates globally with more than 5,000 highly qualified
people. The Company's sites in Europe and the USA offer highly synergistic
technologies and services and operate as complementary clusters of
excellence. For additional information please go to www.evotec.com and
follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

For further information, please contact:

Media

Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com

Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com


---------------------------------------------------------------------------

08.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1941589

End of News EQS News Service
---------------------------------------------------------------------------

1941589 08.07.2024 CET/CEST